Novo Nordisk A/S Common Stock (NY:NVO)

37.32 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

99 100 Next >

Marjorie Taylor Greene Buys 6 Stocks And Bitcoin ETF: Here's Her Latest Shopping List ↗

October 22, 2025

Congresswoman Marjorie Taylor Greene (R-Ga.) is among the most active traders in Congress. Here's a look at her latest trades disclosed, which comes with increased attention on Congress Trades from...

Via Benzinga

Novo Nordisk Shares Tumble Amid Sweeping Board Overhaul

October 22, 2025

Copenhagen, Denmark – October 22, 2025 – Novo Nordisk (NYSE: NVO) shares experienced a notable decline this week following the announcement of a comprehensive board overhaul, a decisive move...

Via MarketMinute

3 Things Investors Need to Know Ahead of Eli Lilly's Q3 Earnings Report ↗

October 22, 2025

The rapid growth rates of recent years aren't guaranteed to continue.

Via The Motley Fool

Topics Intellectual Property

Omeros Corp Stock Soars A Whopping 136% Pre-Market After Novo Nordisk Agrees To Buy Its Drug Candidate For Blood Disorder ↗

October 15, 2025

Via Stocktwits

These 3 Beaten-Down Healthcare Stocks Could Have Farther to Fall ↗

October 21, 2025

Don't try to catch a falling surgical knife.

Via The Motley Fool

Topics Government

Did Eli Lilly Just Say "Checkmate" to Novo Nordisk? ↗

October 21, 2025

The tides continue to change in Eli Lilly's favor in the GLP-1 space.

Via The Motley Fool

Behind the Scenes of Novo Nordisk's Latest Options Trends ↗

October 20, 2025

Via Benzinga

2 Beaten-Down Stocks to Buy and Hold for the Next Decade ↗

October 20, 2025

That's plenty of time for these drugmakers to move past their challenges.

Via The Motley Fool

These 3 Obesity Drug Stocks Are Set to Soar This Fall and Beyond ↗

October 20, 2025

These companies are jockeying for position in a potential $150 billion market opportunity.

Via The Motley Fool

'No Place Is Risk-Free Until The World Is Polio-Free:' Bill Gates Urges Global Action To Close Deadly Immunity Gaps ↗

October 19, 2025

Polio cases drop 99.9%, but funding shortfall could undo progress. Last mile hardest as virus exploits immunity gaps.

Via Benzinga

Benzinga Bulls And Bears: Stellantis, Papa John's, Oklo — And Trade Tensions Shake Chip Stocks ↗

October 18, 2025

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Via Benzinga

Topics World Trade

Trump's Weight-Loss Drug Push May Put These ETFs On A Diet ↗

October 17, 2025

Trump's vow to slash weight-loss drug prices sent Hims & Hers tumbling. These ETFs are facing new pressure.

Via Benzinga

Topics ETFs Government

Trump-Induced Volatility Aside, Novo Trades Cheap While Patents Protect Its Profits Until 2032 ↗

October 17, 2025

Novo Nordisk offers cheap stock with strong moat and long-term growth tailwinds. Trump's drug price cut suggestion caused short-term volatility but...

Via Benzinga

Topics Government Intellectual Property

Novo Nordisk Stock Is Falling Friday: What's Driving The Action? ↗

October 17, 2025

Shares of Danish pharmaceutical giant Novo Nordisk are trading lower Friday morning, continuing an after-hours slide that began Thursday.

Via Benzinga

Trump Pledges To Cut Obesity Drug Prices. Novo Nordisk, Eli Lilly Stocks Dive. ↗

October 17, 2025

Novo Nordisk and Eli Lilly stocks slumped Friday after President Donald Trump said he would cut the price of obesity drugs.

Via Investor's Business Daily

Topics Government

Novo Nordisk Hires US Pharma Veteran After Trump Touts ‘Much Lower’ Prices Of Ozempic ↗

October 17, 2025

Greg Miley stated that he will join Novo Nordisk next month as the company’s senior vice president of corporate affairs.

Via Stocktwits

Topics Government

Eli Lilly Shares Are Trading Lower Friday: What's Going On? ↗

October 17, 2025

Eli Lilly shares are trading lower Friday, among other GLP-1 drug manufacturers, following Trump's comments that fat-loss drugs will be a lot lower in price.

Via Benzinga

Topics Government

Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs? ↗

October 17, 2025

Trump's promise to cut cost of Novo Nordisk A/S drug Ozempic from $1,300 to $150 shakes GLP-1 gold rush, with potential impact on Eli Lilly and Pfizer.

Via Benzinga

Topics Government

Market Jitters: Dow Dips Amid Bank Fears While Eli Lilly and Novo Nordisk Tumble on Trump's Drug Pricing Comments

October 17, 2025

The financial markets experienced a turbulent Friday, October 17, 2025, as the Dow Jones Industrial Average faced a downturn driven by a resurgence of fears within the banking sector. Concurrently,...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Regional Banks’ Credit Concerns Drag Dow Futures: NVO, WAL, ZION, IBKR Among Stocks To Watch ↗

October 17, 2025

While Dow Jones futures were down by 0.13% at the time of writing, the S&P 500 futures declined 0.41%.

Via Stocktwits

Topics ETFs Earnings Fraud

Eli Lilly vs. Viking Therapeutics Stock: Which Is the Best Growth Opportunity, According to Wall Street? ↗

October 17, 2025

These stocks have climbed in the triple digits over the past few years.

Via The Motley Fool

Eli Lilly, Novo Nordisk Stocks Fall After-Hours As Trump Pledges Swift Price Cuts For ‘Fat-Loss Drugs’ ↗

October 16, 2025

Novo Nordisk is also continuing discussions with the administration under the Most Favored Nation policy aimed at linking U.S. drug costs to global benchmarks.

Via Stocktwits

Topics Economy Government

Eli Lilly, Novo Nordisk, Hims & Hers Health Shares Move Lower After Trump Calls Out 'Fat-Loss Drugs' ↗

October 16, 2025

Shares of Eli Lilly and Novo Nordisk move lower in Thursday's after-hours session after President Trump indicated weight-loss drugs are going to go down in price.

Via Benzinga

Topics Government

What's Driving the Market Sentiment Around Novo Nordisk AS? ↗

October 16, 2025

Via Benzinga

Hims & Hers Stock's 150% Surge Is All Fundamentals—No Novo, No Problem ↗

October 16, 2025

Hims & Hers (HIMS) has seen surprising success, up 150% YTD, driven by their new menopause specialty and refocusing on healthcare.

Via Benzinga

A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now? ↗

October 16, 2025

Find out if the deal Omeros announced is enough of a reason to buy this stock.

Via The Motley Fool

Omeros Stock Logs Best Session Ever After HC Wainwright Doubles Target On Novo Nordisk Deal; Retail Sees Big Upside ↗

October 15, 2025

The rally followed H.C. Wainwright’s price target hike to $20 on the back of a $2.1 billion licensing deal with Novo Nordisk for zaltenibart.

Via Stocktwits

Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead ↗

October 15, 2025

Novo Nordisk’s $4.7B Akero deal boosts its metabolic health pipeline, targeting Eli Lilly’s lead in obesity and liver disease treatments

Via MarketBeat

Topics World Trade

Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal ↗

October 15, 2025

Omeros stock jumps 164% as Novo Nordisk acquires global rights to zaltenibart, with potential milestones reaching $2.1 billion and tiered royalties.

Via Benzinga

Meet the 1.4% Yield Dividend Stock That Could Soar in 2026 ↗

October 15, 2025

The company is one of two major players in the rapidly growing obesity drug market. Yet, the stock has lost half its value.

Via The Motley Fool

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.